APA (7th ed.) Citation

NW, C., A, A., FC, I., A, H., CL, A., G, A., . . . ND, J. (2019). Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), 1992. https://doi.org/10.1093/annonc/mdz396

Chicago Style (17th ed.) Citation

NW, Clarke, et al. "Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results from the STAMPEDE Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology 30, no. 12 (2019): 1992. https://doi.org/10.1093/annonc/mdz396.

MLA (9th ed.) Citation

NW, Clarke, et al. "Addition of Docetaxel to Hormonal Therapy in Low- and High-burden Metastatic Hormone Sensitive Prostate Cancer: Long-term Survival Results from the STAMPEDE Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 30, no. 12, 2019, p. 1992, https://doi.org/10.1093/annonc/mdz396.